Green tea and cardiovascular disease: From molecular targets towards human health

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 11, Issue 6, 2008, Pages 758-765

  Jochmann, Nicoline ^a   Baumann, Gert ^a   Stangl, Verena ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Cardiovascular disease; Catechin; Green tea

Indexed keywords

CATECHIN; EPIGALLOCATECHIN GALLATE; GREEN TEA EXTRACT; LIPID; OXIDIZED LOW DENSITY LIPOPROTEIN; POLYPHENOL; THEAFLAVIN;

ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ATHEROMA; ATHEROSCLEROSIS; BIOAVAILABILITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM; CELL FUNCTION; CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIET THERAPY; DISEASE COURSE; DRUG EFFECT; ENDOTHELIUM CELL; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; IN-STENT RESTENOSIS; INOTROPISM; INSULIN DEPENDENT DIABETES MELLITUS; LIPID BLOOD LEVEL; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; REVIEW; SINGLE DRUG DOSE; TEA; THROMBOSIS; VASCULAR ENDOTHELIUM;

ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; BEVERAGES; CARDIOVASCULAR DISEASES; CATECHIN; ENDOTHELIUM, VASCULAR; HUMANS; PLANT EXTRACTS; TEA;

EID: 55149087679     PISSN: 13631950     EISSN: 15353885     Source Type: Journal    
DOI: 10.1097/MCO.0b013e328314b68b     Document Type: Review

References (95)

1. Balentine DA, Wiseman SA, Bouwens LC. The chemistry of tea flavonoids. Crit Rev Food Sci Nutr 1997; 37:693-704.
2. Shahidi F. Antioxidants in food and food antioxidants. Nahrung 2000; 3:158-163.
3. Stangl V, Lorenz M, Stangl K. The role of tea and tea flavanoids in cardiovascular health. Mol Nutr Food Res 2006; 50:218-228.
4. Yang CS, Sang S, Lambert JD, Lee MJ. Bioavailability issues in studying the health effects of plant polyphenolic compounds. Mol Nutr Food Res 2008; 52:139-151. A conclusive review regarding the bioavailability of polyphenols with a focus on tea catechins.
5. Lambert JD, Sang S, Yang CS. Biotransformation of green tea polyphenols and the biological activities of those metabolites. Mol Pharm 2007; 4:819-825.
6. Lu H, Meng X, Li C, et al. Glucuronides of tea catechins: enzymology of biosynthesis and biological activities. Drug Metab Dispos 2003; 31:452-461.
7. Nakagawa H, Hasumi K, Takami M, et al. Identification of two biologically crucial hydroxyl groups of (-)-epigallocatechin gallate in osteoclast culture. Biochem Pharmacol 2007; 73:34-43.
8. Sato Y, Nakatsuka H, Watanabe T, et al. Possible contribution of green tea drinking habits to the prevention of stroke. Tohoku J Exp Med 1989; 157:337-343.
9. Nakachi K, Matsuyama S, Miyake S, et al. Preventive effects of drinking green tea on cancer and cardiovascular disease: epidemiological evidence for multiple targeting prevention. Biofactors 2000; 13:49-54.
10. Iwai N, Ohshiro H, Kurozawa Y, et al. Relationship between coffee and green tea consumption and all-cause mortality in a cohort of a rural Japanese population. J Epidemiol 2002; 12:191-198.
11. Kuryiami S, Shimazu T, Ohmori K, et al. Green tea consumption and mortality due to cardiovascular disease, cancer, and all causes in Japan. JAMA 2006; 296:1255-1265.
12. Peters U, Poole C, Arab L Does tea affect cardiovascular disease? A metaanalysis. Am J Epidemiol 2001; 154:495-503.
13. Hayek T, Fuhrman B, Vaya J, et al. Reduced progression of atherosclerosis in apolipoprotein E-deficient mice following consumption of red wine, or its polyphenols quercetin or catechin, is associated with reduced susceptibility of LDL to oxidation and aggregation. Vase Biol 1997; 17:2744-2752.
14. Xu R, Yokoyama WH, Irving D, et al. Effect of dietary catechin and vitamin E on aortic fatty streak accumulation in hypercholesterolemic hamsters. Atherosclerosis 1998; 137:29-36.
15. Miura Y, Chiba T, Tomita I, et al. Tea catechins prevent the development of atherosclerosis in apoprotein E-deficient mice. J Nutr 2001; 131:27-32.
16. Koo SI, Noh SK. Green tea as inhibitor of the intestinal absorption of lipids: potential mechanism for its lipid-lowering effect. J Nutr Biochem 2007; 18:179-183. A conclusive review regarding the effects of green tea on enterai lipid absorption.
17. Vinson JA, Dabbagh YA. Effect of green and black tea supplementation on lipids, lipid oxidation and fibrinogen in the hamster: mechanisms for the epidemiological benefits of tea drinking. FEBS Lett 1998; 433:44-46.
18. Unno T, Tago M, Suzuki Y, et al. Effect of tea catechins on postprandial plasma lipid responses in human subjects. Br J Nutr 2005; 93:543-547.
19. Maron DJ, Lu GP, Cai NS, et al. Cholesterol-lowering effect of a theaflavin-enriched green tea extract: a randomized controlled trial. Arch Intern Med 2003; 163:1448-1453.
20. Tsubono Y, Tsugane S. Green tea intake in relation to serum lipid levels in middle-aged Japanese men and women. Ann Epidemiol 1998; 7:280-284.
21. Stensvold I, Tverdal A, Solvoll K, Foss OP. Tea consumption relationship to cholesterol, blood pressure, and coronary and total mortality. Prev Med 1992; 21:546-553.
22. Yang Y, Lu FH, Wu JS, et al. The protective effect of habitual tea consumption on hypertension. Arch Intern Med 2004; 164:1534-1540.
23. Antonello M, Montemurro D, Bolognesi M, et al. Prevention of hypertension, cardiovascular damage and endothelial dysfunction with green tea extracts. Am J Hypertens 2007; 20:1321-1328. An animal study that revealed prevention of arterial hypertension and target-organ damage following supplementation by green tea extract.
24. Lorenz M, Wessler S, Follmann E, et al. A constituent of green tea, epigallo-catechin-3-gallate, activates endothelial nitric oxide synthase by a phosphatidyinositol-3-OH-kinase, cAMP-dependent protein kinase-, and Akt-dependent pathway and leads to endothelial-dependent vasorelaxation. Biol Chem 2004; 279:6190-6195.
25. Potenza MA, Marasciulo FL, Tarquinio M, et al. EGCG, a green tea polyphenol, improves endothelial function and insulin sensitivity, reduces blood pressure, and protects against myocardial I/R injury in SHR. Am J Physiol Endocrinol Metab 2007; 292:1378-1387. A study on a rat model of metabolic syndrome, which provides new insights into the mechanisms of EGCG action.
26. Murase T, Nagasawa A, Suzuki J, et al. Beneficial effects of tea catechins on diet-induced obesity: stimulation of lipid catabolism in the liver, Int J Obes 2002; 26:1459-1464.
27. Zheng G, Sayama K, Okubo T, et al. Antiobesity effects of three major components of green tea, catechins, caffeine and theanine, in mice. In Vivo 2004; 18:55-62.
28. Dulloo AG, Duret C, Rohrer D, et al. Efficacy of a green tea extract rich in catechin polyphenols and caffeine in increasing 24-h energy expenditure and fat oxidation in humans. Am J Clin Nutr 1999; 70:1040-1045.
29. Chantre P, Lairon D. Recent findings of green tea extract AR25 (Exolise) and its activity for the treatment of obesity. Phytomedicine 2002; 9: 3-8.
30. Nagao T, Komine Y, Soga S, et al. Ingestion of a tea rich in catechins leads to a reduction in body fat and malondialdehyde-modified LDL in men. Am J Clin Nutr 2005; 81:122-129.
31. Westerterp-Plantega MS, Lejeune MP, Kovacs EM. Body weight loss and weight maintenance in relation to habitual caffeine intake and green tea supplementation. Obes Res 2005; 13:1195-2104.
32. Hsu C-H, Tsai T-H, Kao Y-H, et al. Effect of green tea extract on obese women: a randomized, double-blind, placebo-controlled clinical trial. Clin Nutr 2008; 27:363-370. A very well designed randomized, double-blind, placebo-controlled clinical trial on 78 humans.
33. Murase T, Haramizu S, Shimotoyodome A, Tokimitsu I. Reduction of diet-induced obesity by a combination of tea-catechin intake and regular swimming, Int J Obes 2006; 30:561 -568.
34. Shimotoyodome A, Haramizu S, Inaba M, et al. Exercise and green tea extract stimulate fat oxidation and prevent obesity in mice. Med Sci Sports Exerc 2005; 37:1884-1892.
35. Song EK, Hur H, Han MK. Epigallocatechin gallate prevents autoimmune diabetes induced by multiple low doses of streptozotocin in mice. Arch Pharm Res 2003; 26:559-563.
36. Wolfram S, Wang Y, Thielecke F. Antiobesity effects of green tea: from bedside to bench. Mol Nutr Food Res 2006; 50:176-187.
37. Collins QF, Liu H-Y, Pi J, et al. Epigaltocatechin-3-gallate (EGCG), a green tea polyphenol, suppresses hepatic gluconeogenesis through 5'-AMP-activated protein kinase. J Biol Chem 2007; 282:30143-30149. A study on isolated hepatocytes that demonstrates an inhibitory role for EGCG in gluconeogenesis.
38. Venables MC, Hulston CJ, Cox HR, Jeukendrup AE. Green tea extract ingestion, fat oxidation, and glucose tolerance in healthy humans. Am J Clin Nutr 2008; 87:778-784. A study with a relative small sample size (n = 12) that, for the first time, shows in humans an increase in fat oxidation during exercise after consumption of green tea extract.
39. Vinson JA, Teufel K, Wu N. Green and black teas inhibit atherosclerosis by lipid, antioxidant, and fibrinolytic mechanisms. J Agric Food Chem 2004; 52:3661-3665.
40. Stangl V, Dreger H, Stangl K, Lorenz M. Molecular targets of tea polyphenols in the cardiovascular system. Cardiovasc Res 2007; 73:348-358. A conclusive review, which enables insights into the molecular cardiovascular actions of tea polyphenols.
41. Lee KW, Lee HJ. Antioxidant activity of black tea vs. green tea. J Nutr 2002; 132:785.
42. Rice-Evans CA, Miller NJ, Paganga G. Structure-antioxidant activity relationships of flavonoids and phenolic acids. Free Radic Biol Med 1996; 20:933-956.
43. Frei B, Higdon JV. Antioxidant activity of tea polyphenols in vivo: evidence from animal studies. J Nutr 2003; 133:3275-3284.
44. Wu CC, Hsu MC, Hsieh CW, et al. Upregulation of heme-oxygenase-1 by epigallocatechin-3-gallate via the phosphatidylinositol 3-kinase/Akt and ERK pathways. Life Sci 2006; 78:2889-2897.
45. Nanjo F, Honda M, Okushio K, et al. Effects of dietary tea catechms on alphatocopherol levels, lipid peroxidation, and erythrocyte deformability in rats fed on high palm oil and perilla oil diets. Biol Pharm Bull 1993; 16:1156-1159.
46. 2+ mediated oxidative modification of low density lipoprotein. Biol Pharm Bull 1994; 17:1567-1572.
47. Serafini M, Ghiselli A, Ferro-Luzzi A. In vivo antioxidant effect of green and black tea in men. Eur J Clin Nutr 1996; 50:28-32.
48. Soriani M, Rice-Evans C, Tyrrell RM. Modulation of the UVA activation of haem oxygenase, collagenase and cyclooxygenase gene expression by epigallocatechin in human skin cells. FEBS Lett 1998; 439:253-257.
49. Wang LJ, Lee TS, Lee FY, et al. Expression of heme oxygenase-1 in atherosclerotic lesions. Am J Pathol 1998; 152:711-720.
50. Lee W, Min WK, Chun S, et al. Long-term effects of green tea ingestion on atherosclerotic biological markers in smokers. Clin Biochem 2005; 38:84-87.
51. Van het Hof KH, de Boer HS, Wiseman SA, et al. Consumption of green or black tea does not increase resistance of low-density lipoprotein to oxidation in humans. Am J Clin Nutr 1997; 66:1125-1132.
52. Van het Hof KH, Kivits GA, Weststrate JA, Tijburg LB. Bioavailability of catechins from tea: the effect of milk. Eur J Clin Nutr 1998; 52:356-359.
53. Leenen R, Roodenburg AJ, Tijburg LB, Wiseman SA. A single dose of tea with or without milk increases plasma antioxidant activity in humans. Eur J Clin Nutr 2000; 54:87-92.
54. Hodgson JM, Puddey IB, Croft KD, et al. Acute effects of ingestion of black and green tea on lipoprotein oxidation. Am J Clin Nutr 2000; 71:1103-1107.
55. Huang Y, Chan NW, Lau CW, et al. Involvement of endothelium/nitric oxide in vasorelaxation induced by purified green tea (-)-epicatechin. Biochem Biophys Acta 1999; 1427:322-328.
56. Andriambeloson E, Magnier C, Haan-Archipoff G, et al. Natural dietary polyphenolic compounds cause endothelium-dependent vasorelaxation in rat thoracic aorta. J Nutr 1998; 128:2324-2333.
57. Sanae F, Miyaichi Y, Kizu H, Hyashi H. Effects of catechins on vascular tone in rat thoracic aorta with endothelium. Life Sci 2002; 71:2553-2562.
58. 2-mediated multiple-signalling pathways. Clin Exp Pharmacol Physiol 2003; 30:88-95.
59. Nagaya N, Yamamoto H, Uematsu M, et al. Green tea reverses endothelial dysfunction in healthy smokers. Heart 2004; 90:1485-1486.
60. Alvarez E, Campos-Toimil M, Justiniano-Basaran J, et al. Study of the mechanisms involved in the vasorelaxation induced by (-)-epigallocatechin-3- gallate in rat aorta. Br J Pharmacol 2006; 147:269-280.
61. Tang WJ, Hu CP, Chen MF, et al. Epigallocatechin gallate preserves endothelial function by reducing the endogenous nitric oxide synthase inhibitor level. Can J Physiol Pharmacol 2006; 84:163-171.
62. Kim W, Jeong MH, Cho SH, et al. Effect of green tea consumption on endothelial function and circulating endothelial progenitor cells in chronic smokers. Circ J 2006; 70:1052-1057.
63. Kim J, Formoso G, Li Y, et al. Epigallocatechin gallate, a green tea polyphenol, mediates NO-dependent vasodilation using signalling pathways in vascular endothelium requiring reactive oxygen species and Fyn. J Biol Chem 2007; 282:13736-13745. A study that shows a possible link between the antioxidative and beneficial effects of EGCG on endothelial function.
64. Widlansky ME, Hamburg NM, Anter E, et al. Acute EGCG supplementation reverses endothelial dysfunction in patients with coronary artery disease. J Am Coll Nutr 2007; 26:95-102. The first study on humans that investigates beneficial effects of EGCG supplementation on endothelial function.
65. Jochmann N, Lorenz M, Krosigk A, et al. The efficacy of black tea in ameliorating endothelial function is equivalent to that of green tea. Br J Nutr 2008; 99:863-868. The first comparison of the effects of green and black tea consumption on endothelial function in humans.
66. Sueoka N, Suganuma M, Sueoka E, et al. A new function of green tea: prevention of lifestyle-related diseases. Ann N Y Acad Sci 2001; 928:274-280.
67. Cheng TO. Why did green tea not protect against coronary artery disease but protect against myocardial infarction? Am J Cardiol 2003; 91:1290-1291.
68. Hofbauer R, Frass M, Gmeiner B, et al. The green tea extract epigallocatechin gallate is able to reduce neutrophil transmigration through monolayers of endothelial cells. Wien Klin Wochenschr 1999; 111:278-282.
69. Koga T, Meydani M. Effect of plasma metabolites of (+)-catechin and quercetin on monocyte adhesion to human aortic endothelial cells. Am J Clin Nutr 2001; 73:941-948.
70. Ludwig A, Lorenz M, Grembo N, et al. The tea flavanoid epigallocatechin-3-gallate reduces cytokine-induced VCAM-1 expression and monocyte adhesion to endothelial cells. Biochem Biophys Res Commun 2004; 316:659-665.
71. Ahn HY, Xu Y, Davidge ST. Epigallocatechin-3-O-gallate inhibits TNFα-induced monocyte chemotactic protein-1 production from vascular endothelial cells. Life Sci 2008; 82:964-968. An in-vitro study with a novel description of the mechanism of the anti-inflammatory effects of EGCG.
72. κB signalling. Life Sci 2007; 80:1957-1965. An in-vitro study with a novel description of the mechanism of the anti-inflammatory effects of EGCG.
73. Chyu KY, Babbidge SM, Zhao X, et al. Differential effects of green tea-derived catechin on developing versus established atherosclerosis in apolipoprotein E-null mice. Circulation 2004; 109:2448-2453.
74. El Bedoui J, Oak MH, Anglard P, Schini-Kerth VB. Catechins prevent vascular smooth muscle cell invasion by inhibiting MT1-MMP activity and MMP-2 expression. Cardiovasc Res 2005; 67:317-325.
75. Kim DW, Park YS, Kim YG, et al. Local delivery of green tea catechins inhibits neointimal formation in the rat carotid artery injury model. Heart Vessels 2004; 19:242-247.
76. Kang WS, Lim IH, Yuk DY, et al. Antithrombotic activities of green tea catechins and (-)-epigallocatechin gallate. Thromb Res 1999; 96:229-237.
77. Landolfi R, Mower RL, Steiner M. Modification of platelet function and arachidonic acid metabolism by bioflavonoids. Structure-activity relations. Biochem Pharmacol 1984; 33:1525-1530.
78. Son DJ, Cho MR, Jin YR, et al. Antiplatelet effect of green tea catechins: a possible mechanism through arachidonic acid pathway. Prostaglandins Leukot Essent Fatty Acids 2004; 71:25-31.
79. Sagesaka-Mitane Y, Miwa M, Okada S. Platelet aggregation inhibitors in hot water extract of green tea. Chem Pharm Bull (Tokyo) 1990; 38:790-793.
80. Sugatani J, Fukazawa N, Ujihara K, et al. Tea polyphenols inhibit acetyl-CoA: 1-alkyl-sn-glycero-3-phosphocholine acetyltransferase (a key enzyme in platelet-activating factor biosynthesis) and platelet-activating factor-induced platelet aggregation. Arch Allergy Immunol 2004; 134:17-28.
81. 2 production, and maintaining calcium-ATPase activity. J Cardiovasc Pharmacol 2008; 51:45-54. An in-vitro study that investigates the molecular signalling pathways of EGCG antiplatelet activity.
82. ε-caprolactone) as stent coating materials. Biomaterials 2008; 29:884-893. An interesting innovative in-vitro study on VSCM that raises the possibility of using EGCG as a stent coating material.
83. Kubota Y, Umegaki K, Tanaka N, et al. Safety of dietary supplements: chronotropic and inotropic effects on isolated rat atria. Biol Pharm Bull 2002; 25:197-200.
84. 2+ and nitric oxide release. Eur J Pharm 2006; 552:123-130.
85. ε-dependent regulation of myocardial contraction by epicatechin-3-gallate. Am J Physlol Heart Circ Physiol 2008; 294:345-353. A study on isolated rat hearts that employs a Langendorff-perfusion system for investigation of the positive inotropic effects of catechins.
86. 2+ exchangers. Eur J Heart Fail 2008; 10:439-445. A study on isolated rat cardiomyocytes that characterizes the effects of EGCG on myocardial contractility and studies the underlying mechanisms.
87. 2+ exchangers. J Mol Cell Cardiol 2006; 41:807-815.
88. Li HL, Huang Y, Zhang CN, et al. Epigallocatechin-3 gallate inhibits cardiac hypertrophy through blocking reactive oxidative species-dependent and -independent signal pathways. Free Radic Biol Med 2006; 40:1756-1775.
89. Hao J, Kim CH, Ha TS, Ahn HY. Epigallocatechin-3 gallate prevents cardiac hypertrophy induced by pressure overload in rats. J Vet Sci 2007; 8:121-129. An animal study that reveals prevention of cardiac hypertrophy with EGCG supplementation.
90. Priyadarshi S, Valentine B, Han C, et al. Effect of green tea extract on cardiac hypertrophy following 5/6 nephrectomy in the rat. Kidney Int 2003; 63:1785-1790.
91. Hunstein W. Epigallocatechin-3 gallate in AL amyloidosis: a new therapeutic option? Blood 2007; 110:2216. An interesting case report offering a therapeutic option for green tea consumption.
92. Suzuki J, Ogawa M, Futamatsu H, et al. Tea catechins improve left ventricular dysfunction, suppress myocardial inflammation and fibrosis, and alter cytokine expression in rat autoimmune myocarditis. Eur J Heart Fail 2007; 9:152-159. A study on an autoimmune myocarditis model in rats, with conclusion that catechins could be a promising tool in treatment of myocarditis.
93. Townsend PA, Scarabelli TM, Pasini E, et al. Epigallocatechin-3- gallate inhibits STAT-1 activation and protects cardiac myocytes from ischemia/ reperfusion-induced apoptosis. FASEB J 2004; 18:1621-1623.
94. Suzuki J, Ogawa M, Maejima Y, et al. Tea catechins attenuate chronic ventricular remodeling after myocardial ischemia in rats. J Mol Cell Cardiol 2007; 42:432-440. A study that shows how oral administration of catechins in rats with myocardial ischaemia suppresses chronic ventricular remodelling.
95. 2-mediated oxidative stress in neonatal cardiomyocytes and shows the cardioprotective effects of EGCG against oxidative stress.